Results 181 to 190 of about 769,984 (331)

Treatment options for immune‐related adverse events associated with immune checkpoint inhibitors

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract The immunotherapy revolution with the use of immune checkpoint inhibitors (ICIs) started with the clinical use of the first ICI, ipilimumab, in 2011. Since then, the field of ICI therapy has rapidly expanded — with the FDA approval of 10 different ICI drugs so far and their incorporation into the therapeutic regimens of a range of malignancies.
Yu Hua Chen   +3 more
wiley   +1 more source

Organizing Government for the 21st Century

open access: yesCanadian Public Administration, EarlyView.
Abstract The last major reorganization of the federal government was undertaken by Prime Minister Campbell in 1993. Today, there is a new set of considerations that a new government must bear in mind to deal with a very different and much more uncertain world.
James R. Mitchell
wiley   +1 more source

Update on Menopause Hormone Therapy; Current Indications and Unanswered Questions

open access: yesClinical Endocrinology, EarlyView.
ABSTRACT Objective To provide clinicians involved in managing menopause with a summary of current evidence surrounding menopause hormone therapy (MHT). Design The authors evaluate and synthesize existing pooled evidence relating to MHT's clinical indications, efficacy, and safety and explore the limitations of existing data. Patients The review focuses
Annice Mukherjee, Susan R. Davis
wiley   +1 more source

Progressive systemic sclerosis in a child: A rare phenomenon

open access: yesIndian Journal of Paediatric Dermatology, 2017
Savita Arya   +3 more
doaj   +1 more source

T cells from newly diagnosed multiple sclerosis patients have enhanced responsiveness to CD46 activation

open access: yesClinical and Experimental Neuroimmunology, EarlyView.
Abstract Objective To evaluate the responsiveness of T cells from newly diagnosed multiple sclerosis (MS) patients to CD46 co‐stimulation, a membrane co‐factor protein potentially involved in MS pathogenesis. Methods T cells from MS patients and non‐diseased symptomatic controls (SC) were activated in vitro with or without αCD46 antibody co‐stimulation.
Linda Sundvall   +6 more
wiley   +1 more source

Serum Angiopoietin-like Protein 3 Levels: Possible Correlation with Progressive Skin Sclerosis, Digital Ulcers and Pulmonary Vascular Involvement in Patients with Systemic Sclerosis

open access: gold, 2014
Yohei Ichimura   +14 more
openalex   +1 more source

The Application of Polymeric Nanoparticles as Drug Delivery Carriers to Cells in Neurodegenerative Diseases

open access: yesCell Proliferation, EarlyView.
Polymeric nanoparticles represent promising drug (gene) delivery carriers to the brain due to their unique advantages to facilitate the penetration of blood–brain barrier and endocytosis of neuronal cells in neurodegenerative diseases. ABSTRACT In spite of great advances in modern medicine, there are a few effective strategies for the treatment of ...
Lian Jin   +4 more
wiley   +1 more source

Exercise Delays Brain Ageing Through Muscle‐Brain Crosstalk

open access: yesCell Proliferation, EarlyView.
This graphical abstract illustrates the reciprocal crosstalk between the brain and peripheral organs, highlighting the profound impact of exercise on brain health through systemic interactions. It underscores how exercise influences the brain via signals from various organs and, conversely, how the brain modulates functions of peripheral organs.
Shirin Pourteymour   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy